The 2020 Information Note No. 1 of the SOBERANA 01 Clinical Trial indicates that the only adverse effect recorded was mild pain at the injection site, which is a side effect, common to all vaccines.
On August 24, Cuban scientists began clinical trials of Soberana 01 with a group of 20 individuals ranging in age from 19 to 59 years.
On September 3, the vaccine was administered to another group of 20 volunteers whose ages ranged between 60 and 80 years.
Besides confirming that they are in good health, the volunteers indicated that a mild pain at the injection site was the only adverse effect.
On September 11, the Cuban vaccine will enter the next phase of clinical testing in which 676 volunteers will participate. Although the investigation must conclude all its stages in January 2021, the results of the study will be available at the end of November.
In Latin America, Cuba is the only country whose scientists have received authorization to conduct clinical trials of a domestically produced vaccine.
This technological achievement is the consequence of decades of accumulated research in preventive medicine and mass immunization. It is also the result of a biopharmaceutical industry with the capacity to compete with pharmaceutical transnationals.
In Cuba, all citizens will have free access to the COVID-19 vaccine through the public health system.
